lOMoARcPSD|210 076 14
Pharmacotherapeutics for Advanced Practice- A
I I I I
PracticalApproach 5th Edition Arcangelo Test Bank
I I I I I I I
Pharmacology Ifor IAdvanced IPractice INursing I(Kennesaw IState IUniversity)
, lOMoARcPSD|210 076 14
Chapter I1 IIssues Ifor Ithe IPractitioner Iin IDrug ITherapy
MULTIPLE ICHOICE
1. Nurse Ipractitioner Iprescriptive Iauthority Iis Iregulated Iby:
A. The INational ICouncil Iof IState IBoards Iof INursing
B. The IU.S. IDrug IEnforcement IAdministration
C. The IState IBoard Iof INursing Ifor Ieach Istate
D. The IState IBoard Iof IPharmacy
ANS: I C PTS: I 1
2. Physician IAssistant I(PA) Iprescriptive Iauthority Iis Iregulated Iby:
A. The INational ICouncil Iof IState IBoards Iof INursing
B. The IU.S. IDrug IEnforcement IAdministration
C. The IState IBoard Iof INursing
D. The IState IBoard Iof IMedical IExaminers
ANS: I D PTS: I 1
3. Clinical Ijudgment Iin Iprescribing Iincludes:
A. Factoring Iin Ithe Icost Ito Ithe Ipatient Iof Ithe Imedication Iprescribed
B. Always Iprescribing Ithe Inewest Imedication Iavailable Ifor Ithe Idisease Iprocess
C. Handing Iout Idrug Isamples Ito Ipoor Ipatients
D. Prescribing Iall Igeneric Imedications Ito Icut Icosts
ANS: I A PTS: I 1
4. Criteria Ifor Ichoosing Ian Ieffective Idrug Ifor Ia Idisorder Iinclude:
A. Asking Ithe Ipatient Iwhat Idrug Ithey Ithink Iwould Iwork Ibest Ifor Ithem
B. Consulting Inationally Irecognized Iguidelines Ifor Idisease Imanagement
C. Prescribing Imedications Ithat Iare Iavailable Ias Isamples Ibefore Iwriting Ia Iprescription
D. Following IU.S. IDrug IEnforcement IAdministration I(DEA) Iguidelines
I forIprescribing
ANS: I B PTS: I 1
5. Nurse Ipractitioner Ipractice Imay Ithrive Iunder Ihealth-care Ireform Idue Ito:
A. The Idemonstrated Iability Iof Inurse Ipractitioners Ito Icontrol Icosts Iand Iimprove
Ipatient Ioutcomes
B. The Ifact Ithat Inurse Ipractitioners Iwill Ibe Iable Ito Ipractice Iindependently
C. The Ifact Ithat Inurse Ipractitioners Iwill Ihave Ifull Ireimbursement Iunder Ihealth-
careIreform
D. The Iability Ito Ishift Iaccountability Ifor IMedicaid Ito Ithe Istate Ilevel
ANS: I A PTS: I 1
Downloaded Iby IPatrick ILiquete
I()
, lOMoARcPSD|210 076 14
Chapter I2.Pharmacokinetic IBasis Iof ITherapeutics Iand IPharmacodynamic
MULTIPLE ICHOICE
1. A Ipatient's Inutritional Iintake Iand Ilab Iwork Ireflects Ihypoalbuminemia. IThis Iis
I critical ItoIprescribing Ibecause:
A. Distribution Iof Idrugs Ito Itarget Itissue Imay Ibe Iaffected
B. The Isolubility Iof Ithe Idrug Iwill Inot Imatch Ithe Isite Iof Iabsorption
C. There Iwill Ibe Iless Ifree Idrug Iavailable Ito Igenerate Ian Ieffect
D. Drugs Ibound Ito Ialbumin Iare Ireadily Iexcreted Iby Ithe Ikidney
ANS: I A PTS: I 1
2. Drugs Ithat Ihave Ia Isignificant Ifirst-pass Ieffect:
A. Must Ibe Igiven Iby Ithe Ienteral I(oral) Iroute Ionly
B. Bypass Ithe Ihepatic Icirculation
C. Are Irapidly Imetabolized Iby Ithe Iliver Iand Imay Ihave Ilittle Iif Iany Idesired Iaction
D. Are Iconverted Iby Ithe Iliver Ito Imore Iactive Iand Ifat-soluble Iforms
ANS: I C PTS: I 1
3. The Iroute Iof Iexcretion Iof Ia Ivolatile Idrug Iwill Ilikely Ibe:
A. The Ikidneys
B. The Ilungs
C. The Ibile Iand Ifeces
D. The Iskin
ANS: I B PTS: I 1
4. Medroxyprogesterone I(Depo IProvera) Iis Iprescribed IIM Ito Icreate Ia Istorage Ireservoir Iof
ItheIdrug. IStorage Ireservoirs:
A. Assure Ithat Ithe Idrug Iwill Ireach Iits Iintended Itarget Itissue
B. Are Ithe Ireason Ifor Igiving Iloading Idoses
C. Increase Ithe Ilength Iof Itime Ia Idrug Iis Iavailable Iand Iactive
D. Are Imost Icommon Iin Icollagen Itissues
ANS: I C PTS: I 1
5. The INP Ichooses Ito Igive Icephalexin Ievery I8 I hours Ibased Ion Iknowledge Iof Ithe Idrug's:
A. Propensity Ito Igo Ito Ithe Itarget Ireceptor
B. Biological Ihalf-life
C. Pharmacodynamics
D. Safety Iand Iside Ieffects
ANS: I B PTS: I 1
6. Azithromycin Idosing Irequires Ithe Ifirst Iday's Idose Ibe Itwice Ithose Iof Ithe Iother I4 Idays
Iof ItheIprescription. IThis I is Iconsidered Ia I loading I dose. IA I loading Idose:
A. Rapidly Iachieves Idrug Ilevels Iin Ithe Itherapeutic Irange
B. Requires Ifour Ito Ifive Ihalf-lives Ito Iattain
C. Is Iinfluenced Iby Irenal Ifunction
, lOMoARcPSD|210 076 14
D. Is Idirectly Irelated Ito Ithe Idrug Icirculating Ito Ithe Itarget Itissues
ANS: I A PTS: I I I 1
7. The Ipoint Iin Itime Ion Ithe Idrug Iconcentration Icurve Ithat Iindicates Ithe Ifirst Isign Iof Ia
ItherapeuticIeffect I is Ithe:
A. Minimum Iadverse Ieffect Ilevel
B. Peak Iof Iaction
C. Onset Iof Iaction
D. Therapeutic Irange
ANS: I C PTS: I 1
8. Phenytoin Irequires Ia Itrough Ilevel Ibe Idrawn. IPeak Iand Itrough Ilevels Iare Idone:
A. When Ithe Idrug Ihas Ia Iwide Itherapeutic Irange
B. When Ithe Idrug Iwill Ibe Iadministered Ifor Ia Ishort Itime Ionly
C. When Ithere Iis Ia Ihigh Icorrelation Ibetween Ithe Idose Iand Isaturation Iof Ireceptor Isites
D. To Idetermine Iif Ia Idrug Iis Iin Ithe Itherapeutic Irange
ANS: I D PTS: I 1
9. A Ilaboratory Iresult Iindicates Ithe Ipeak Ilevel Ifor Ia Idrug Iis Iabove Ithe Iminimum
ItoxicIconcentration. IThis I means Ithat Ithe:
A. Concentration Iwill Iproduce Itherapeutic Ieffects
B. Concentration Iwill Iproduce Ian Iadverse Iresponse
C. Time Ibetween Idoses Imust Ibe Ishortened
D. Duration Iof Iaction Iof Ithe Idrug Iis Itoo Ilong
ANS: I B PTS: I 1
10. Drugs Ithat Iare Ireceptor Iagonists Imay Idemonstrate Iwhat Iproperty?
A. Irreversible Ibinding Ito Ithe Idrug Ireceptor Isite
B. Up-regulation Iwith Ichronic Iuse
C. Desensitization Ior Idown-regulation Iwith Icontinuous Iuse
D. Inverse Irelationship Ibetween Idrug Iconcentration Iand Idrug Iaction
ANS: I C PTS: I 1
11. Drugs Ithat Iare Ireceptor Iantagonists, Isuch Ias Ibeta Iblockers, Imay Icause:
A. Down-regulation Iof Ithe Idrug Ireceptor
B. An Iexaggerated Iresponse Iif Iabruptly Idiscontinued
C. Partial Iblockade Iof Ithe Ieffects Iof Iagonist Idrugs
D. An Iexaggerated Iresponse Ito Icompetitive Idrug Iagonists
ANS: I B PTS: I 1
12. Factors Ithat Iaffect Igastric Idrug Iabsorption Iinclude:
A. Liver Ienzyme Iactivity
B. Protein-binding Iproperties Iof Ithe Idrug Imolecule
C. Lipid Isolubility Iof Ithe Idrug
D. Ability Ito Ichew Iand Iswallow
ANS: I C PTS: I 1
Pharmacotherapeutics for Advanced Practice- A
I I I I
PracticalApproach 5th Edition Arcangelo Test Bank
I I I I I I I
Pharmacology Ifor IAdvanced IPractice INursing I(Kennesaw IState IUniversity)
, lOMoARcPSD|210 076 14
Chapter I1 IIssues Ifor Ithe IPractitioner Iin IDrug ITherapy
MULTIPLE ICHOICE
1. Nurse Ipractitioner Iprescriptive Iauthority Iis Iregulated Iby:
A. The INational ICouncil Iof IState IBoards Iof INursing
B. The IU.S. IDrug IEnforcement IAdministration
C. The IState IBoard Iof INursing Ifor Ieach Istate
D. The IState IBoard Iof IPharmacy
ANS: I C PTS: I 1
2. Physician IAssistant I(PA) Iprescriptive Iauthority Iis Iregulated Iby:
A. The INational ICouncil Iof IState IBoards Iof INursing
B. The IU.S. IDrug IEnforcement IAdministration
C. The IState IBoard Iof INursing
D. The IState IBoard Iof IMedical IExaminers
ANS: I D PTS: I 1
3. Clinical Ijudgment Iin Iprescribing Iincludes:
A. Factoring Iin Ithe Icost Ito Ithe Ipatient Iof Ithe Imedication Iprescribed
B. Always Iprescribing Ithe Inewest Imedication Iavailable Ifor Ithe Idisease Iprocess
C. Handing Iout Idrug Isamples Ito Ipoor Ipatients
D. Prescribing Iall Igeneric Imedications Ito Icut Icosts
ANS: I A PTS: I 1
4. Criteria Ifor Ichoosing Ian Ieffective Idrug Ifor Ia Idisorder Iinclude:
A. Asking Ithe Ipatient Iwhat Idrug Ithey Ithink Iwould Iwork Ibest Ifor Ithem
B. Consulting Inationally Irecognized Iguidelines Ifor Idisease Imanagement
C. Prescribing Imedications Ithat Iare Iavailable Ias Isamples Ibefore Iwriting Ia Iprescription
D. Following IU.S. IDrug IEnforcement IAdministration I(DEA) Iguidelines
I forIprescribing
ANS: I B PTS: I 1
5. Nurse Ipractitioner Ipractice Imay Ithrive Iunder Ihealth-care Ireform Idue Ito:
A. The Idemonstrated Iability Iof Inurse Ipractitioners Ito Icontrol Icosts Iand Iimprove
Ipatient Ioutcomes
B. The Ifact Ithat Inurse Ipractitioners Iwill Ibe Iable Ito Ipractice Iindependently
C. The Ifact Ithat Inurse Ipractitioners Iwill Ihave Ifull Ireimbursement Iunder Ihealth-
careIreform
D. The Iability Ito Ishift Iaccountability Ifor IMedicaid Ito Ithe Istate Ilevel
ANS: I A PTS: I 1
Downloaded Iby IPatrick ILiquete
I()
, lOMoARcPSD|210 076 14
Chapter I2.Pharmacokinetic IBasis Iof ITherapeutics Iand IPharmacodynamic
MULTIPLE ICHOICE
1. A Ipatient's Inutritional Iintake Iand Ilab Iwork Ireflects Ihypoalbuminemia. IThis Iis
I critical ItoIprescribing Ibecause:
A. Distribution Iof Idrugs Ito Itarget Itissue Imay Ibe Iaffected
B. The Isolubility Iof Ithe Idrug Iwill Inot Imatch Ithe Isite Iof Iabsorption
C. There Iwill Ibe Iless Ifree Idrug Iavailable Ito Igenerate Ian Ieffect
D. Drugs Ibound Ito Ialbumin Iare Ireadily Iexcreted Iby Ithe Ikidney
ANS: I A PTS: I 1
2. Drugs Ithat Ihave Ia Isignificant Ifirst-pass Ieffect:
A. Must Ibe Igiven Iby Ithe Ienteral I(oral) Iroute Ionly
B. Bypass Ithe Ihepatic Icirculation
C. Are Irapidly Imetabolized Iby Ithe Iliver Iand Imay Ihave Ilittle Iif Iany Idesired Iaction
D. Are Iconverted Iby Ithe Iliver Ito Imore Iactive Iand Ifat-soluble Iforms
ANS: I C PTS: I 1
3. The Iroute Iof Iexcretion Iof Ia Ivolatile Idrug Iwill Ilikely Ibe:
A. The Ikidneys
B. The Ilungs
C. The Ibile Iand Ifeces
D. The Iskin
ANS: I B PTS: I 1
4. Medroxyprogesterone I(Depo IProvera) Iis Iprescribed IIM Ito Icreate Ia Istorage Ireservoir Iof
ItheIdrug. IStorage Ireservoirs:
A. Assure Ithat Ithe Idrug Iwill Ireach Iits Iintended Itarget Itissue
B. Are Ithe Ireason Ifor Igiving Iloading Idoses
C. Increase Ithe Ilength Iof Itime Ia Idrug Iis Iavailable Iand Iactive
D. Are Imost Icommon Iin Icollagen Itissues
ANS: I C PTS: I 1
5. The INP Ichooses Ito Igive Icephalexin Ievery I8 I hours Ibased Ion Iknowledge Iof Ithe Idrug's:
A. Propensity Ito Igo Ito Ithe Itarget Ireceptor
B. Biological Ihalf-life
C. Pharmacodynamics
D. Safety Iand Iside Ieffects
ANS: I B PTS: I 1
6. Azithromycin Idosing Irequires Ithe Ifirst Iday's Idose Ibe Itwice Ithose Iof Ithe Iother I4 Idays
Iof ItheIprescription. IThis I is Iconsidered Ia I loading I dose. IA I loading Idose:
A. Rapidly Iachieves Idrug Ilevels Iin Ithe Itherapeutic Irange
B. Requires Ifour Ito Ifive Ihalf-lives Ito Iattain
C. Is Iinfluenced Iby Irenal Ifunction
, lOMoARcPSD|210 076 14
D. Is Idirectly Irelated Ito Ithe Idrug Icirculating Ito Ithe Itarget Itissues
ANS: I A PTS: I I I 1
7. The Ipoint Iin Itime Ion Ithe Idrug Iconcentration Icurve Ithat Iindicates Ithe Ifirst Isign Iof Ia
ItherapeuticIeffect I is Ithe:
A. Minimum Iadverse Ieffect Ilevel
B. Peak Iof Iaction
C. Onset Iof Iaction
D. Therapeutic Irange
ANS: I C PTS: I 1
8. Phenytoin Irequires Ia Itrough Ilevel Ibe Idrawn. IPeak Iand Itrough Ilevels Iare Idone:
A. When Ithe Idrug Ihas Ia Iwide Itherapeutic Irange
B. When Ithe Idrug Iwill Ibe Iadministered Ifor Ia Ishort Itime Ionly
C. When Ithere Iis Ia Ihigh Icorrelation Ibetween Ithe Idose Iand Isaturation Iof Ireceptor Isites
D. To Idetermine Iif Ia Idrug Iis Iin Ithe Itherapeutic Irange
ANS: I D PTS: I 1
9. A Ilaboratory Iresult Iindicates Ithe Ipeak Ilevel Ifor Ia Idrug Iis Iabove Ithe Iminimum
ItoxicIconcentration. IThis I means Ithat Ithe:
A. Concentration Iwill Iproduce Itherapeutic Ieffects
B. Concentration Iwill Iproduce Ian Iadverse Iresponse
C. Time Ibetween Idoses Imust Ibe Ishortened
D. Duration Iof Iaction Iof Ithe Idrug Iis Itoo Ilong
ANS: I B PTS: I 1
10. Drugs Ithat Iare Ireceptor Iagonists Imay Idemonstrate Iwhat Iproperty?
A. Irreversible Ibinding Ito Ithe Idrug Ireceptor Isite
B. Up-regulation Iwith Ichronic Iuse
C. Desensitization Ior Idown-regulation Iwith Icontinuous Iuse
D. Inverse Irelationship Ibetween Idrug Iconcentration Iand Idrug Iaction
ANS: I C PTS: I 1
11. Drugs Ithat Iare Ireceptor Iantagonists, Isuch Ias Ibeta Iblockers, Imay Icause:
A. Down-regulation Iof Ithe Idrug Ireceptor
B. An Iexaggerated Iresponse Iif Iabruptly Idiscontinued
C. Partial Iblockade Iof Ithe Ieffects Iof Iagonist Idrugs
D. An Iexaggerated Iresponse Ito Icompetitive Idrug Iagonists
ANS: I B PTS: I 1
12. Factors Ithat Iaffect Igastric Idrug Iabsorption Iinclude:
A. Liver Ienzyme Iactivity
B. Protein-binding Iproperties Iof Ithe Idrug Imolecule
C. Lipid Isolubility Iof Ithe Idrug
D. Ability Ito Ichew Iand Iswallow
ANS: I C PTS: I 1
